294 related articles for article (PubMed ID: 23159947)
1. The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.
Fiorillo AA; Medler TR; Feeney YB; Wetz SM; Tommerdahl KL; Clevenger CV
Am J Pathol; 2013 Jan; 182(1):217-33. PubMed ID: 23159947
[TBL] [Abstract][Full Text] [Related]
2. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
3. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
4. Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2016 Oct; 7(40):65602-65613. PubMed ID: 27564112
[TBL] [Abstract][Full Text] [Related]
5. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
6. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
7. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Plotnikov A; Varghese B; Tran TH; Liu C; Rui H; Fuchs SY
Cancer Res; 2009 Apr; 69(7):3165-72. PubMed ID: 19276348
[TBL] [Abstract][Full Text] [Related]
8. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of prolactin receptor in breast cancer cells.
Li Y; Clevenger CV; Minkovsky N; Kumar KG; Raghunath PN; Tomaszewski JE; Spiegelman VS; Fuchs SY
Oncogene; 2006 Mar; 25(13):1896-902. PubMed ID: 16278670
[TBL] [Abstract][Full Text] [Related]
10. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
11. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer.
Ormandy CJ; Hall RE; Manning DL; Robertson JF; Blamey RW; Kelly PA; Nicholson RI; Sutherland RL
J Clin Endocrinol Metab; 1997 Nov; 82(11):3692-9. PubMed ID: 9360527
[TBL] [Abstract][Full Text] [Related]
12. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland.
Hovey RC; Trott JF; Ginsburg E; Goldhar A; Sasaki MM; Fountain SJ; Sundararajan K; Vonderhaar BK
Dev Dyn; 2001 Oct; 222(2):192-205. PubMed ID: 11668597
[TBL] [Abstract][Full Text] [Related]
16. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
[TBL] [Abstract][Full Text] [Related]
17. Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development.
Grimm SL; Seagroves TN; Kabotyanski EB; Hovey RC; Vonderhaar BK; Lydon JP; Miyoshi K; Hennighausen L; Ormandy CJ; Lee AV; Stull MA; Wood TL; Rosen JM
Mol Endocrinol; 2002 Dec; 16(12):2675-91. PubMed ID: 12456789
[TBL] [Abstract][Full Text] [Related]
18. Endocrine control of canine mammary neoplasms: serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors.
Spoerri M; Guscetti F; Hartnack S; Boos A; Oei C; Balogh O; Nowaczyk RM; Michel E; Reichler IM; Kowalewski MP
BMC Vet Res; 2015 Sep; 11():235. PubMed ID: 26370564
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.
Lee SA; Haiman CA; Burtt NP; Pooler LC; Cheng I; Kolonel LN; Pike MC; Altshuler D; Hirschhorn JN; Henderson BE; Stram DO
BMC Med Genet; 2007 Dec; 8():72. PubMed ID: 18053149
[TBL] [Abstract][Full Text] [Related]
20. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
